Who Paid My Doc
Ashwin Basavaraj
Pulmonary Disease New York, NY Medical Doctor
NPI 1386803351 CMS profile 1307117
550 First Avenue, Nyu Langone Medical Center, New York, NY 10016
General payments
$46,839
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$127,425
Through program year 2025, Ashwin Basavaraj of New York, NY is reported in the CMS Open Payments database as having received $46,839 across 82 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $127,425 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 93rd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $29 | 1 | |
| 2023 | General | $14,180 | 25 | |
| 2022 | General | $10,153 | 16 | |
| 2021 | General | $4,126 | 10 | |
| 2020 | General | $7,403 | 13 | |
| 2019 | General | $10,948 | 17 |
Beside peers
- Ashwin Basavaraj
- Pulmonary Disease median
- Middle half of Pulmonary Disease
- National median
In program year 2025, general payments to Ashwin Basavaraj were reported at $29. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.
Show as a table
| Year | Ashwin Basavaraj | Pulmonary Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $10,948 | $377 | $109–$1,340 | $163 |
| 2020 | $7,403 | $230 | $56–$907 | $114 |
| 2021 | $4,126 | $269 | $68–$1,072 | $132 |
| 2022 | $10,153 | $390 | $100–$1,457 | $149 |
| 2023 | $14,180 | $419 | $114–$1,659 | $160 |
| 2024 | $0 | $476 | $123–$1,818 | $164 |
| 2025 | $29 | $500 | $124–$1,893 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 15 drugsPart D claims
454
Drug cost
$548,154
Branded share of claims
57%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Arikayce Amikacin Liposomal/Neb.Accessr | Brand | 29 | $427,655 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 69 | $52,259 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 57 | $32,771 | |
| Spiriva Handihaler Tiotropium Bromide | Brand | 17 | $12,561 | |
| Incruse Ellipta Umeclidinium Bromide | Brand | 19 | $7,151 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 12 | $5,110 | |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | Brand | 14 | $3,477 | |
| Amikacin Sulfate | Generic | 19 | $2,286 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 42 | $1,374 | |
| Ethambutol Hcl | Generic | 43 | $1,240 |
The 10 drugs with the highest cost, of 15 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 23 billing codesPaid by Medicare
$84,278
Medicare patients
282
Services billed
1,631
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| COPD | 75% | |
| High blood pressure | 65% | |
| Ischemic heart disease | 61% | |
| Arthritis | 58% | |
| Osteoporosis | 40% | |
| Diabetes | 26% | |
| Cancer | 26% | |
| Depression | 25% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg J7613 | Office | 99 | 278 | $11 |
| Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg J7612 | Office | 13 | 14 | $3 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
82 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pulmonary Disease in New York
Related records
Pulmonary Disease in New York
Practitioners in the same specialty and state, ranked by reported value.
All Pulmonary Disease
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.